About Regado

MEDICAL ADVISORY BOARD

Professor of Medicine
Director, Duke Clinical Research Institute
Duke University Medical Center
Durham, NC

Dr. Harrington received his undergraduate degree in English from the College of the Holy Cross, Worcester, MA. He attended Dartmouth Medical School and received his medical degree from Tufts University School of Medicine in 1986. He was an intern, resident and the Chief Medical Resident in internal medicine at the University of Massachusetts Medical Center. He was a fellow in cardiology at Duke University Medical Center, where he received training in interventional cardiology and research training in the Duke Databank for Cardiovascular Diseases. He joined the Duke faculty in the Division of Cardiology in 1993, where he is currently a Professor of Medicine and an interventional cardiologist.

His research interests include evaluating antithrombotic therapies to treat acute ischemic heart disease and to minimize the acute complications of percutaneous coronary procedures, studying the mechanism of disease of the acute coronary syndromes, understanding the issues of risk stratification in the care of patients with acute ischemic coronary syndromes, trying to better understand and improve upon the methodology of clinical trials. He is the recipient of an NIH Roadmap contract to investigate “best practices” among clinical trial networks.

He has authored multiple peer-reviewed manuscripts, reviews, book chapters, and editorials. He is one of the senior co-editors for the 8th edition of the American College of Chest Physicians’ Consensus Panel on Antithrombotic and Thrombolytic Drugs. He is an Associate Editor of the American Heart Journal and an editorial board member for the Journal of the American College of Cardiology. He is a Fellow of the American College of Cardiology, the American Heart Association, the Society of Cardiovascular Angiography and Intervention and the American College of Chest Physicians. He is currently a member of the Board of Trustees of the American College of Cardiology, chairs the American College of Cardiology Clinical Expert Consensus Document Task Force and the Science and Clinical Policy Subcommittee, co-chairs the Education Oversight Committee and is a member of the Clinical Quality Committee. He currently serves as chair of the FDA Cardiovascular and Renal Drugs Advisory Committee. He chaired the 2006 Annual Scientific Sessions for the American College of Cardiology. He is currently a member of the NHLBI’s study section for clinical trials and is a member of the NHLBI Working Group on Clinical Trials Methodology.

Professor, Department of Medicine (Cardiology)
University of Alberta, Edmonton, Alberta, Canada
Director of the Canadian VIGOUR Centre (Virtual Coordinating Centre for Global Collaborative Cardiovascular Research) 

As founding Director of TORCH (TomorrOw’s Research Cardiovascular Health Professionals),  Dr. Armstrong is committed to the training of cardiovascular researchers.  He is a Senior Attending Cardiologist at the University of Alberta Hospital with particular interest and expertise in acute coronary care and heart failure.  He is founding and immediate past President of the Canadian Academy of Health Sciences.

Dr Armstrong received his medical degree at Queen’s University. After post-graduate training both there and at the University of Toronto, he undertook clinical and research training in cardiology at the Massachusetts General Hospital, Harvard Medical School and St. George’s Hospital, London, UK.  From 1972 until 1984 he served as the first Director of the Coronary Care Unit at the Kingston General Hospital, Queen’s University. In 1984, he assumed the position of Chief of Cardiology at St Michael’s Hospital and Professor of Medicine at the University of Toronto. From 1993 to 1999, he served as Professor and Chair of the Department of Medicine, University of Alberta.

Dr. Armstrong’s investigative career has developed along two major lines of inquiry. The first involved the study of the pathophysiology and novel therapeutic approaches of congestive heart failure. The second, now his principal focus, involves the pathophysiology, diagnosis and management of acute coronary syndromes.  His role as chair of the international VIGOUR group has lead to multiple leadership and executive positions on large scale international clinical trials of novel strategies in acute coronary syndromes that have helped to transform the care of patients world wide.

Dr. Armstrong frequently serves as visiting professor and invited lecturer in institutions and major scientific meetings both in Canada and internationally.  He is the author, or co-author, of over 450 peer reviewed publications and a member of a number of editorial boards including the Canadian Medical Association Journal, Circulation, the Journal of the American College of Cardiology, the American Heart Journal and the European Heart Journal. He is a member of the American College of Cardiology/American Heart Association ST Elevation Myocardial Infarction Guidelines writing committee, CIHR’s Institute of Circulatory and Respiratory Health’s Advisory Board and former member of the FDA Cardiovascular and Renal Advisory Committee and the Board of the Council of the Canadian Academies. 

Dr. Armstrong has had a lifelong commitment to the education and training of healthcare professionals. Numerous of his former trainees, residents and research fellows have gone onto to faculty/ academic positions in all regions of the country and internationally.  His mentorship of trainees and faculty have been a key signature of his career and recognized both nationally and internationally.

Dr. Armstrong has received numerous awards including the Research Achievement Award of the Canadian Cardiovascular Society in 1993, the Award of Merit from the Heart and Stroke Foundation in 1998 and the Robert Beamish leadership award in 2002. In 2004 he received the Prix Galien Canada Research Award (awarded to the researcher or the research team judged to have made the most significant contribution to pharmaceutical research in Canada). In 2006, he became the first recipient of the University of Alberta Faculty of Medicine & Dentistry’s Annual Award for Excellence in Clinical Mentoring. He was chosen by the Canadian Society of Clinical Investigation as the 2006 G. Malcolm Brown Lecturer awarded for excellence in scientific and academic endeavours and was chosen by the University of Freiburg to deliver the 2006 Greats of Cardiology Award Lecture the highest honour their Heart Centre awards to a distinguished person in the cardiovascular field. The University of Alberta awarded him the title of University Professor in 2006 for outstanding distinction in each of the areas of scholarly research, teaching, service to the university and the community at large. In 2007, he received the most prestigious award for excellence in research from the University of Alberta named after J. Gordin Kaplan.  In 2008, he received the Christie Award (Canadian Association of Professors of Medicine) – to recognize outstanding contributions to academic medicine.

Professor of Medicine and Director, Duke Cardiovascular Thrombosis Center
Duke Clinical Research Institute
Durham, North Carolina

Dr Becker previously spent over a decade at the University of Massachusetts Medical Center, serving in various capacities including Professor of Medicine, and Director of the Cardiovascular Thrombosis Research Center, Coronary Care Unit and Anticoagulation Services. He is a member of numerous professional associations such as the International Atherosclerosis Society, the International Society on Thrombosis and Hemostasis and the Thrombosis Council of the American Heart Association. Dr Becker has been the recipient of several professional and academic honours including, most recently, the Outstanding Mentorship Award from Duke University, and Teacher of the Year and the Education Achievement ‘Star’ Award from the University of Massachusetts School of Medicine.

Dr Becker has published over 350 articles in peer-reviewed journals and authored twelve textbooks. He is the founding editor-in-chief of the Journal of Thrombosis and Thrombolysis, now in its fourteenth year of publication. His current research, supported by the National Institutes of Health and the Duke Translational Research Institute, focuses on gene expression profiles and advanced proteomics and molecular platforms of drug development, including RNA aptamers and drug-antidote pairs. Dr Becker received his MEd in biochemistry and his MD from the University of Cincinnati Graduate School and College of Medicine, respectively, in Ohio. He completed fellowships in Hematology at the Cleveland Clinic and Cardiovascular Medicine at the University of Massachusetts Medical Center.

Dr. Becker, as the Director, Cardiovascular Thrombosis Research Center at the Duke Clinical Research Institute will be involved directly in all aspects of the proposed research. He is an NIH-funded investigator in the field of platelet biology, and as co-Director, Biomarkers Program coordinates several multi-dimensional research projects that employ gene expression profile and proteomic platforms to determine signatures of thrombosis.

Vice Chancellor for Clinical Research
Professor of Medicine
Duke University Medical Center
Director, Duke Translational Medicine Institute
Durham, North Carolina

Dr. Califf was born in Anderson, South Carolina, in 1951 and attended high school in Columbia, SC, where he was a member of the 1969 AAAA South Carolina Championship basketball team.  He graduated from Duke University, summa cum laudeand Phi Beta Kappa, in 1973 and from Duke University Medical School in 1978, where he was selected for Alpha Omega Alpha. He performed his internship and residency at the University of California at San Francisco and his fellowship in cardiology at Duke University. He is board-certified in internal medicine (1984) and cardiology (1986) and is a Master of the American College of Cardiology (2006).

He is currently Vice Chancellor for Clinical Research, Director of the Duke Translational Medicine Institute (DTMI), and Professor of Medicine in the Division of Cardiology at the Duke University Medical Center in Durham, North Carolina. For 10 years he was the founding Director of the Duke Clinical Research Institute (DCRI), the premier academic research organization in the world. He is the editor-in-chief of Elsevier’s American Heart Journal, the oldest cardiovascular specialty journal. He has been author or coauthor of more than 900 peer-reviewed journal articles and a contributing editor for theheart.org, an online information resource for academic and practicing cardiologists.  He was recently acknowledged as one of the 10 most cited authors in the field of medicine by the Institute for Scientific Information (ISI).

He has led the DCRI efforts for many of the best-known clinical trials in cardiovascular disease. With his colleagues from the Duke Databank for Cardiovascular Disease, he has written extensively about clinical and economic outcomes in chronic heart disease and is considered an international leader in the fields of health outcomes, quality of care, and medical economics. DTMI contains 5 institutes, including the DCRI and institutes focused on the bench to bedside research, proof of concept research, point of care clinical research and community based research.  It has an annual budget of over $150 million more than 1000 employees, with extensive global collaborations with government agencies, the medical products industry, and academic partners.

Dr. Califf has served on the Cardiorenal Advisory Panel of the U.S. Food and Drug Administration (FDA) and the Pharmaceutical Roundtable of the Institute of Medicine (IOM). He also served on the IOM Committee that recommended Medicare coverage of clinical trials, which Congress recently approved. He was the founding director of coordinating center for the Centers for Education & Research on Therapeutics™ (CERTs), a public-private partnership among the Agency for Healthcare Research and Quality, academia, the medical products industry, and consumer groups. This partnership focuses on research and education that will advance the best use of medical products.  He is now Co-Chair of the Clinical Trials Transformation Initiative (CTTI), a public private partnership with the FDA, academia, industry and multiple government agencies.  CTTI is attempting to improve the operational conduct of clinical trials.

Associate Professor
McMaster University
Haematologist, Hamilton General Hospital
Hamilton, Ontario, Canada

Dr. Eikelboom completed training in Internal Medicine and Haematology in Perth, Australia in 1998 and subsequently undertook a fellowship in Thrombosis Medicine and Clinical Epidemiology at McMaster University. He returned to McMaster in 2005 to take up a Tier II Canada Research Chair in Cardiovascular Medicine. Dr Eikelboom has published more than 170 articles in peer-reviewed journals. His current research, supported by the Canadian Institutes for Health Research, the Heart and Stroke Foundation and the National Health and Medical Research Council of Australia, focuses on the efficacy and safety of antithrombotic therapies in arterial and venous thrombosis, the prognostic importance of bleeding and transfusion, and the mechanisms of variable response to antiplatelet drugs.

Associate Professor of Medicine
Chief, Clinical Research, Cardiovascular Division
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Dr. Gibson received his MD from the University of Chicago. He was an Intern, Resident and Chief Resident at the Brigham and Women’s Hospital, Harvard Medical School. He received his training as an interventional cardiologist and served as the Director of the Coronary Care Unit at Beth Israel Hospital, Harvard Medical School. Dr. Gibson’s work has largely focused on investigating the pathophysiology of coronary artery disease and the efficacy of pharmacologic and device based therapies. His work has been presented in over 1000 manuscripts, abstracts, trial summaries, textbooks and textbook chapters.

Over 20 years ago, Dr. Gibson founded PERFUSE, an academic research organization which has served as the angiographic core laboratory and data coordinating center for a wide variety of studies including acute MI studies, unstable angina studies, interventional cardiology trials, peripheral interventional trials, venographic trials, angiogenesis trials (VEGF), imaging modality studies, managed care analyses for HCFA, and atherosclerosis regression trials such as the NIH-sponsored Harvard Atherosclerosis Reversibility Project (HARP). He directed the TIMI angiographic core laboratory and invented the TIMI frame count (CTFC) in which the number of cineframes for dye to reach standardized distal landmarks is counted (an index of epicardial blood flow). Gibson also invented the TIMI myocardial perfusion grade (the blush, a measure of microvascular perfusion). The TIMI frame count and the TIMI myocardial perfusion grade are both multivariate predictors of 2 year mortality in acute MI, and are now widely used both clinically and in the assessment of new reperfusion strategies. The methods invented by Gibson and his reasearch have played a critical role in our understanding of "the open artery hypothesis" and more recently in what Gibson has termed "the open muscle hypothesis". On Google scholar, the TIMI Frame Count is listed as being cited in about 2,000 articles.  Under Gibson's direction, PERFUSE created the master database that unified data from over 25 years of TIMI studies (TIMI 1-50) in nearly 100,000 patients and coordinated data analyses for the TIMI study group and functioned as the TIMI Data Coordinating Center. Within the Thrombolysis In Myocardial Infarction (TIMI) Study Group, Dr. Gibson has served as a Principle Investigator of multiple international trials within the TIMI Study Chairman’s Office.

Dr. Gibson is Founder and Chairman of the Board of WikiDoc Foundation (a 509 (a)(1) Charitable Organization). This is the world's largest medical textbook / encyclopedia. There are currently over 25,000 page views daily of over 75,000 chapters of content contributed by over 900 registered users.

Dr. Gibson also edited a textbook entitled “Management Strategies in Interventional Cardiology” which is optimized for hand held devices. In the past, Gibson has authored the chapter on Primary Angioplasty in Randomized Trials in Cardiovascular Disease published as a companion to Braunwald's Heart Disease. In the past he has co-authored the chapter “Recognition and Management of Patients with Stable Angina Pectoris in Braunwald and Goldman’s Primary Cardiology. He has served as lead author of the section on myocardial perfusion imaging in a imaging textbook which is a companion to Braunwald’s Heart Disease.

Dr. Gibson is on the editorial board of Circulation and Editor-in-Chief of Clinical Trial Results where he created the first weekly TV show for Cardiologists "This Week in Cardiology". Gibson also created TIMI.org, the website of the TIMI Study Group.

Dr. Gibson lectures internationally on the topics of interventional cardiology, antithrombotics, antiplatelet agents, acute coronary syndromes, atherosclerosis and lipid-lowering, the future of medical communication and the concept of "copyleft" as well as pay for performance. In 2007, Gibson was selected by Who's Who as the Clinical Researcher of the Year.

Medical Director, Cardiac Catheterization Laboratories
The Methodist DeBakey Heart Center
The Methodist Hospital
Houston, Texas
Professor of Medicine, Weill Medical College, Cornell University

After receiving his medical degree from Columbia University of Physicians and Surgeons in New York, Dr. Kleiman completed an internship and residency in Internal Medicine at Baylor College of Medicine in Houston.  He then completed a fellowship in Cardiology also at Baylor College of Medicine.

Dr. Kleiman has published over 200 manuscripts, book chapters and abstracts.  His work has appeared in such publications as the Journal of the American College of Cardiology, Annals of Thoracic Surgery, Journal of Cardiovascular Pharmacology, Circulation, The American College of Cardiology, and The European Heart Journal.  In addition, he is on the editorial board of several journals including The Journal of Interventional Cardiology, Circulation, The American Heart Journal, and The Journal of Thrombosis and Thrombolysis.

Dr. Kleiman is a member of a number of professional organizations including The American Heart Association Council on Clinical Cardiology and Council on Thrombosis, and he is a fellow of The American College of Cardiology and the Society for Coronary Angiography and Interventions.

Director, Center for Clinical Research and Vice Chairman for Clinical Research
Cleveland Clinic Lerner Research Institute
Vice Chairman, Department of Cardiovascular Medicine
Director, Cleveland Clinic Coordinating Center for Clinical Research (C5Research)
Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
The Cleveland Clinic Foundation, Cleveland, OH

Dr. Lincoff’s research activities focus on development of therapies to reduce acute and long-term complications of percutaneous coronary revascularization procedures, to optimize therapy for acute coronary ischemic syndromes, or reduce progression or complications of atherosclerosis.  He has served as principal investigator or steering committee member of over 15 pivotal trials in ischemic heart disease, enrolling in aggregate over 50,000 patients, studying new antiplatelet or antithrombotic agents in the settings of coronary intervention, heart attack, or unstable angina.

Dr. Lincoff is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.  He holds the Charles and Charlotte Fowler Endowed Chair for Cardiovascular Research at the Cleveland Clinic.

Dr. Lincoff has authored or coauthored over 200 peer-reviewed articles, including publications in the New England Journal of Medicine, Journal of the American Medical Association, Lancet, Annals of Internal Medicine, Circulation, Journal of the American College of Cardiology, American Heart Journal, and European Heart Journal.  He is editor of a book entitled Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, now in its second edition.  He has also authored over 80 book chapters and reviews and presented over 300 lectures at various medical meetings and courses throughout the world.  He is the Consulting Editor of the American Journal of Cardiovascular Drugs and serves on editorial boards or as a reviewer for over 15 peer-reviewed scientific journals.

Dr. Lincoff is currently a member of the Cardiovascular and Renal Drugs Advisory Committee of the United States Food and Drug Administration.

Dr. Lincoff is a fellow of the American College of Cardiology and the European Society of Cardiology and a member of the American College of Physicians, scientific councils of the American Heart Association, and the Sigma Xi Scientific Research Society.

Associate Professor of Medicine, Columbia University Medical Center
Joint Chief Scientific Officer, Clinical Trial Center
Cardiovascular Research Foundation
New York, New York

Dr. Mehran is a practicing interventional cardiologist at New York-Presbyterian Hospital/Columbia University Medical Center. She spent several years as an interventional cardiologist before becoming Director of Clinical Research at the Cardiology Research Foundation at the Washington Hospital Center and later relocated to New York to assume her current post.
           
Dr. Mehran has a longstanding research interest in cardiovascular topics, including intravascular ultrasound, angioplasty, and coronary stenting, and has written over 200 publications on these topics, including the chapter, "Coronary Heart Disease," in the book Principles and Practice of Interventional Cardiology.
           
Dr. Mehran completed her training in internal medicine at the University of Connecticut. She then continued her studies in cardiovascular medicine and interventional cardiology at the Cardiovascular Institute at Mount Sinai Medical Center in New York City.

Professor of Thoracic and Cardiovascular Surgery
University of Paris Descartes
Chief of the Cardiac Surgery Unit
Hôpital Européen Georges Pompidou
Paris, France

Dr Menasché obtained his MD and PhD degrees from the University of Paris. In addition to his clinical positions, he is currently Director of an INSERM (National Institute of Health and Medical Research) laboratory devoted to cell therapy of cardiovascular diseases. He started to work in this area 15 years ago and performed in 2000 the first human intramyocardial transplantation of autologous skeletal myoblasts in a patient with severe heart failure. He was then the PI of a randomised controlled trial of myoblast transplantation designed to assess the safety and efficacy of the technique. The suboptimal results of this study has then led the group to refocus on the use of cardiac progenitors derived from human embryonic stem cells (ESC), in close collaboration with the team of Michel Pucéat. The laboratory is using small and large animal (including nonhuman primate) models of myocardial infarction and, in parallel with studies on myocardial regeneration by ESC-derived cardiac progenitors, is extensively involved in the optimisation of cell delivery techniques with the objective of a clinical translation in patients with end-stage heart failure who have exhausted conventional therapies. Other areas of interest include myocardial protection during heart surgery and, more specifically, cardiac transplantation.

Professor of Cardiology
Uppsala Clinical Research Centre
University Hospital
Uppsala, Sweden

Lars Wallentin became the first Professor of Cardiology at Uppsala University Hospital, Uppsala, Sweden in 1991 and was Head of the Department of Cardiology from 1991 to 1999. He founded the Cardiothoracic Center at Uppsala, becoming its first Chairman in 1994 - 1995, and going on to serve as Vice Chairman from 1995 to 1999. In 2001, Professor Wallentin founded the Uppsala Clinical Research Center, where he has been the Director 2002 - 2008. In 1992 he started and became the first chairman of the Swedish Registry of Acute Cardiac Care (RIK-HIA). Thereafter he has contributed to the development of several National registries of other heart diseases e.g. coronary interventions (SCAAR), secondary prevention (SEPHIA) and atrial fibrillation and anticoagulation (AURICULA). In 2002, he founded and became the director of the First Swedish Competence Center for national Quality Registers in Health Care which now is responsible for  more than 20 registries in different areas of health care in Sweden and internationally. Over the last 20 years professor Wallentin has been the chairman and principal investigator of many national and international clinical trials of new treatment concepts in cardiac diseases. Currently he is the leader of several global clinical trials including more than 60.000 patients investigating not only the effects of new pharmaceutical agents but also the genetic and biochemical basis for cardiovascular diseases.

The group of Lars Wallentin has developed many new concepts concerning pathogenesis, diagnosis, risk stratification, and antithrombotic and interventional treatments in acute coronary artery diseases. Over the last 20 years, they have pioneered the use of molecular biomarkers and new treatments concepts in acute coronary artery diseases.

Prof Wallentin has published more than 300 papers in peer-reviewed international journals, in addition to a large numbers of other publications and book chapters and has received several prestigious research awards. He is a member of numerous medical societies, task forces, working groups and editorial boards, and is an expert for the Swedish Board of Health and Welfare. From 1998 to 1999, Professor Wallentin was President of the Swedish Cardiac Society, and from 2000 to 2002, he founded and served as President of the Swedish Heart Association. Currently, Professor Wallentin is Chairman of the Committee for National Guidelines for Treatment of Heart Diseases in Sweden, member of the research council of the Swedish Heart Foundation and expert for the Swedish Government Delegation for the development of Clinical Research.

Honorary Clinical Professor of Medicine
University of Auckland
Director of Coronary Care & Green Lane Cardiovascular Research Unit
Green Lane Cardiovascular Service
Auckland City Hospital
Auckland, New Zealand

Professor White trained as a cardiologist at Green Lane Hospital and at the Harvard Medical School in Boston, Massachusetts, United States. In recognition of his work on end-systolic volume, infarct artery patency and fibrinolysis, he was awarded a Doctorate of Science (DSc) by the University of Otago, New Zealand in 1995 and the 1998 Prince Mahidol Award for Medicine by the King of Thailand.

Professor White is an Honorary Clinical Professor, Department of Medicine at the University of Auckland. He is also an Honorary La’auli Matai (High chief) in Lalomalava, Samoa and a fellow of the Royal Australasian College of Physicians, the American College of Cardiology, the European Society of Cardiology, the American Heart Association, the Cardiac Society of Australia and New Zealand and the Royal Society of New Zealand. 

His special research interests include management of acute ischemic syndromes, cardiovascular disease in the elderly and dyslipidemia. He has more than 500 peer reviewed articles, 55 editorials and 55 Book Chapters. He was invited to give the Paul Dudley White Lecture in 2004 at the American Heart Association Scientific Sessions.

He is also the associate editor of Circulation and editorial board member for international journals including Heart, the Journal of the American College of Cardiology, the American Heart Journal, the European Heart Journal and the heart.org. He is also a Section Editor, for the Clinical Trials section in Current opinion in Cardiology.

He chaired the PRISM study and HERO trials. He is also a member of the VIGOUR group and co-chairman of the Redefinition of MI ESC/AHA and the STABILITY Trial. He has served on the steering committees of several international trial groups including ISIS, GUSTO, LIPID and TIMI.